Vyant Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Warrants (Tables)

Warrants (Tables)

3 Months Ended

Mar. 31, 2015

The following table summarizes the warrant activity for the three months ended March 31, 2015:



Issued With / For	Exercise Price			Warrants Outstanding January 1, 2015	2015 Warrants Exercised	Warrants Outstanding March 31, 2015
Non-Derivative Warrants:
Financing	$	10.00		243,334	—	243,334
Financing	15.00			436,079	—	436,079
Debt Guarantee	15.00			352,312	—	352,312
Consulting	10.00			29,138	—	29,138
Total Non-Derivative Warrants	$	13.72	B	1,060,863	—	1,060,863
Derivative Warrants:
Financing	$	10.00	A	60,000	—	60,000
Series B Pref. Stock	10.00		A	15,015	—	15,015
Consulting	10.00		A	200	—	200
Total Derivative Warrants	10.00		B	75,215	—	75,215
Total	$	13.47	B	1,136,078	—	1,136,078


A	These warrants are subject to fair value accounting and contain an exercise price adjustment feature. See Note 7.


B	Weighted-average exercise prices are as of March 31, 2015.

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details